We analyzed three other antibodies that target EGFR, are hIgG1, and have been tested in patients: (1) Zalutumumab, tested in phase-1 trial with non-small cell lung cancer (NSCLC) patients (NCT00460551); (2) Nimotuzumab, tested in phase-3 trial with head and neck cancer patients (e.g., NCT00957086); and (3) Necitumumab, approved by the Food and Drug Administration for squamous NSCLC30–32. The gene discussed is EGFR; the disease is head and neck cancer.